Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

• Ramon Colomer ^[2] ; Blanca González Farré ^[3] ; Ana Isabel Ballesteros ^[4] ; Vicente Peg ^[5] ; Begoña Bermejo ^[6] ; Belén Pérez Mies ^[1] ; Susana de la Cruz ^[7] ; Federico Rojo ^[8] ; Sonia Pernas ^[9] ; José Palacios ^[10]
  1. [1] Universidad de Alcalá

     Universidad de Alcalá

     Alcalá de Henares, España

     
  2. [2] UAM Personalised Precision Medicine Chair & Medical Oncology Department, La Princesa University Hospitaland Research Institute, C/Diego de León, 62, 28006 Madrid, Spain
  3. [3] Pathological Anatomy Service, Clínic Hospital, Barcelona, Spain
  4. [4] Medical Oncology Department, La Princesa University Hospital, Madrid, Spain
  5. [5] Pathological Anatomy Service, Vall d’Hebron University Hospital, Barcelona, Spain
  6. [6] Medical Oncology Department, Biomedical Research Institute INCLIVA, Medicine Department of the University of Valencia and Clinic University Hospital, Valencia, Spain
  7. [7] Medical Oncology Department, Navarra University Hospital, Navarre, Spain
  8. [8] Anatomy Service, Fundación Jiménez Díaz University Hospital and CIBERONC, Madrid, Spain
  9. [9] Oncology Department, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet, Barcelona, Spain
  10. [10] Pathological Anatomy Service, Department of Pathology, Ramón y Cajal University Hospital, Faculty of Medicine, University of Alcalá, IRYCIS and CIBERONC, Ctra. Colmenar Viejo, Km 9,1, 28034 Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 12, 2024, págs. 2935-2951
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • This revised consensus statement of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathological Anatomy (SEAP) updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer that we first published in 2018. The expert group recommends determining in early breast cancer the estrogen receptor (ER), progesterone receptor (PR), Ki-67, and Human Epidermal growth factor Receptor 2 (HER2), as well as BReast CAncer (BRCA ) genes in high-risk HER2-negative breast cancer, to assist prognosis and help in indicating the therapeutic options, including hormone therapy, chemotherapy, anti-HER2 therapy, and other targeted therapies. One of the four available genetic prognostic platforms (Oncotype DX ®, MammaPrint ®, Prosigna ®, or EndoPredict ®) may be used in ER-positive patients with early breast cancer to establish a prognostic category and help decide with the patient whether adjuvant treatment may be limited to hormonal therapy. In second-line advanced breast cancer, in addition, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and estrogen receptor 1 (ESR1) should be tested in hormone-sensitive cases, BRCA gene mutations in HER2-negative cancers, and in triple-negative breast cancer (TNBC), programmed cell death-1 ligand (PD-L1). Newer biomarkers and technologies, including tumor-infiltrating lymphocytes (TILs), homologous recombination deficiency (HRD) testing, serine/threonine kinase (AKT) pathway activation, and next-generation sequencing (NGS), are at this point investigational.